Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease
Meniere Disease
About this trial
This is an interventional treatment trial for Meniere Disease focused on measuring Meniere Disease, taVNS, RCT
Eligibility Criteria
Inclusion Criteria:
- Age >=18 and Age <=70.
- Clinical diagnosis of meniere disease.
Exclusion Criteria:
- History of depression, tumors, thyroid disease, diabetes, cardiac diseases.
- History of Otorhinolaryngology surgery.
- Pregnant or lactating women.
Sites / Locations
- Beijing TongRen Hospital, Capital Medical University
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
taVNS group
Control Group
taVNS was applied using a Huatuo stimulator (SDZIIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily. The two electrodes were placed on the cymba conchae and concha around the left ear. Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
tnVNS was applied using a Huatuo stimulator (SDZIIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily. The two electrodes were placed on the antihelix around the left ear. Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.